Is the determination of C-reactive protein really necessary in the diagnosis of Alpha-1 antitrypsin deficiency?

Dear, Editor:

Alpha-1 antitrypsin (AAT) is a medium-sized, water-soluble glycoprotein weighing 52 kDA with a half-life of approximately 5 days and synthesized primarily by hepatocytes. Blood concentrations vary from 1 to 2 g/L (90–220 mg/dl), and as it is an acute phase reactant, its plasma levels can increase 2–4 times in response to inflammatory, infectious, or neoplastic stimuli.1

There are several studies that have evaluated and measured plasma concentrations of AAT according to the different AAT genotypes,2–4 but it was not until the study by Ferrarotti et al.5 that it was considered that as the first step in the algorithm diagnosis of AAT deficiency (AATD), C-reactive protein (CRP) should be previously evaluated as a marker of the existence of conditions that could alter the levels of AAT in blood, since we could find very different values for the same genotype and for both make sure that we were in situations of apparent stability. In addition, it was mentioned that in the studies by Donato and Bomhorst, the range of the concentration of AAT levels for each genotype compared with those found in their study showed important differences, blaming the fact that in both studies, the levels of CRP were not previously measured and, therefore, they were extracted in situations of instability that altered these values.

For all these reasons, it was decided to carry out a prospective observational analytic study consecutively on 1510 subjects who attended the Pulmonology outpatient clinic for any reason, obtaining blood tests and performing genotyped for AAT in the same act, not including measurement of CRP values, most of the subjects were stable, but a percentage presented exacerbations (over 20%) and some of which led to hospital admissions. The study was conducted in accordance with the Declaration of Helsinki and approved by the corresponding ethics committee. All patients were informed of the objectives of the study and signed an informed consent. The inclusion criteria were wanting to participate in the study and being able to take both tests simultaneously. Genotyping was based on the use of so-called hybridization probes or HybProbes,6 and AAT levels were assessed by immunonephelometry. The general results of the patients included in the study showed a median age of 57.5 with a standard deviation of 19.35, and 43.9% of the subjects were women; 19.3% had an active smoking habit, and 35.12% were ex-smokers. Regarding the weight assessed by the body mass index (kg/m²), the median was 28.7, with a standard deviation of 6.09, with a range from 14.9 to 53.6 kg/m². The most prevalent pathologies were obstructive airway diseases (bronchial asthma with 32.2% followed by COPD with 26.5%).

AAT values were analyzed, presenting a median of 123.5 mg/dl with a standard deviation (SD) of 31.8. The ranges of AAT levels obtained corresponding to each genotype were analyzed (Table 1). The overall detection success of deficient variants in the study was 31.4% (Pi*ZZ: 0.5%, Pi*SZ: 1.7%, Pi*SS: 1.5%, Pi*MZ: 7.4%, Pi*MS: 18.4%, and rare variants: 1.4%). The results showed that the measurement of the AAT levels together with the performance of the genotyping in the same act avoided errors and made it unnecessary to obtain the CRP, since it did not matter if the AAT values were increased due to inflammation, infection, or for another reason, since when carrying out the joint genotype, the diagnosis was reached safely, quickly, and efficiently.7 In addition, unnecessary visits and inconveniences for patients (repeat extractions) were avoided. In addition, if we compare the values obtained in our study with those reached by the studies by Donato,3 Bomhorst,4 Vidal,2 and Ferrarotti’s own,5 we reach the conclusion that the difference does exist very small, especially in the lower limits for each genotype, giving greater value if possible, to the results obtained.

In a second phase, the AAT levels obtained for each genotype were divided according to whether or not the patient had an exacerbation (Table 2), confirming that in a stable situation, prior measurement of CRP levels is not necessary.
Therefore, in a patient with chronic respiratory disease (chronic obstructive pulmonary disease or bronchial asthma) and in whom it is desired to screen for the presence of associated AATD, the measurement of CRP levels would be obviated, if it is performed in the same act the determination of AAT levels together with genotyping.

ACKNOWLEDGMENT
The authors have not received funding to write this article.

CONFLICT OF INTEREST
The authors declare no conflicts of interest related directly or indirectly to the contents of the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in Clinical History at https://www3.gobiernodecanarias.org/sanidad/scs/hospitaldelapalma.

Therefore, in a patient with chronic respiratory disease (chronic obstructive pulmonary disease or bronchial asthma) and in whom it is desired to screen for the presence of associated AATD, the measurement of CRP levels would be obviated, if it is performed in the same act the determination of AAT levels together with genotyping.

ACKNOWLEDGMENT
The authors have not received funding to write this article.

CONFLICT OF INTEREST
The authors declare no conflicts of interest related directly or indirectly to the contents of the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in Clinical History at https://www3.gobiernodecanarias.org/sanidad/scs/hospitaldelapalma.

Therefore, in a patient with chronic respiratory disease (chronic obstructive pulmonary disease or bronchial asthma) and in whom it is desired to screen for the presence of associated AATD, the measurement of CRP levels would be obviated, if it is performed in the same act the determination of AAT levels together with genotyping.

ACKNOWLEDGMENT
The authors have not received funding to write this article.

CONFLICT OF INTEREST
The authors declare no conflicts of interest related directly or indirectly to the contents of the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in Clinical History at https://www3.gobiernodecanarias.org/sanidad/scs/hospitaldelapalma.

Therefore, in a patient with chronic respiratory disease (chronic obstructive pulmonary disease or bronchial asthma) and in whom it is desired to screen for the presence of associated AATD, the measurement of CRP levels would be obviated, if it is performed in the same act the determination of AAT levels together with genotyping.

ACKNOWLEDGMENT
The authors have not received funding to write this article.

CONFLICT OF INTEREST
The authors declare no conflicts of interest related directly or indirectly to the contents of the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are openly available in Clinical History at https://www3.gobiernodecanarias.org/sanidad/scs/hospitaldelapalma.

Table 1: Reference ranges (95%) of AAT level (mg/dl) found in a clinical population for different genotypes of the SERPINA1 gene, compared with other authors

| Genotype | Clinical population | Vidal et al. | Donato et al. | Ferrarotti et al. | Bornhorst et al. |
|----------|---------------------|--------------|---------------|-------------------|------------------|
| Pi*MM    | Mean 135.9, SD 25.9, Range 99–197 | 103–200 | 100–273 | 102–175 | 102–254 |
| Pi*MS    | Mean 90.3, SD 12.4, Range 81–179 | 100–180 | 84–225 | 84–147 | 86–218 |
| Pi*MZ    | Mean 85.1, SD 11.8, Range 66–110 | 66–120 | 61–156 | 65–106 | 62–151 |
| Pi*SS    | Mean 90.3, SD 12.4, Range 75–125b | 70–105 | 49–181 | 73–106b | 43–154 |
| Pi*SZ    | Mean 60.1, SD 9.9, Range 44–82b | 45–80 | 42–108 | 49–66b | 38–108 |
| Pi*ZZ    | Mean 18.9, SD 10.6, Range 5–36b | 10–40 | 15–57 | 32b | 29–52 |

aFor the construction of the interval, individuals known, through subsequent analysis, to be carriers of rare deficiency alleles have been eliminated.
bFull range shown due to small number of patients.

Table 2: Reference ranges (95%) of AAT level (mg/dl) found in patients with and without exacerbations for different genotypes of the SERPINA1 gene

| Genotype | With exacerbations (n = 298) | Without exacerbations (n = 1212) |
|----------|-------------------------------|---------------------------------|
| Pi*MM    | Median 153.7, CI (95%) 129.4 (96–178) | Median 134.89 (111–182) 86.7 (82–107) |
| Pi*MS    | Median 134.89 (111–182) 86.7 (82–107) | Median 104.4 (85–110) 82.3 (66–96) |
| Pi*MZ    | Median 104.4 (85–110) 82.3 (66–96) | Median 93 (80–125) 85 (75–96) |
| Pi*SS    | Median 93 (80–125) 85 (75–96) | Median 67 (56–82) 56 (44–66) |
| Pi*SZ    | Median 67 (56–82) 56 (44–66) | Median 22.8 (12.2–36) 16.1 (5–25) |
| Pi*ZZ    | Median 22.8 (12.2–36) 16.1 (5–25) | Median 22.8 (12.2–36) 16.1 (5–25) |

REFERENCES
1. Blanco I, Lara B. Alpha-1 Antitrypsin Deficiency: Pathophysiology, Related Diseases and Treatment. Barcelona: Respira-Spanish Lung Foundation-SEPAR; 2016.
2. Vidal R, Blanco I, Casas F, Jardí R, Miravitlles M. Committee on the National Registry of individuals with Alpha-1 antitrypsin deficiency. Guidelines for the diagnosis and management of Alpha-1 antitrypsin deficiency. Arch Bronconeumol. Dec 2006;42(12):645-659. Spanish. doi:10.1016/s1579-2129(07)60007-x
3. Donato LJ, Jenkins SM, Smith C, Katzmann JA, Snyder MR. Reference and interpretive ranges for α1-antitrypsin quantitation by phenotype in adult and pediatric populations. Am J Clin Pathol. 2012;138(3):398-405. doi:10.1309/AJCPMEEJK32ACYFP
4. Bornhorst JA, Greene DN, Ashwood ER, Grenache DG. Alpha1-antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest. 2013; 143(4):1000-1008. doi:10.1378/chest.12-0564
5. Ferrarotti I, Thun GA, Zorzetto M, et al. Serum levels and genotype distribution of a1-antitrypsin in the general population.

Correspondence
José María Hernández-Pérez, Claudia Viviana López-Charry
Department of Neumology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain.
Email: jmherper@hotmail.com

ORCID
José María Hernández-Pérez https://orcid.org/0000-0002-2920-212X
population. *Thorax*. Aug 2012;67(8):669-674. doi:10.1136/thoraxjnl-2011-201321

6. Hernández Pérez JM, Ramos Díaz R, Fumero García S, Pérez Pérez JA. Description of Alpha-1-antitrypsin deficiency associated with PI*Q0ourém allele in La Palma Island (Spain) and a genotyping assay for its detection. *Archivos de Bronconeumología*. 2015;51(1):e1-e3. doi:10.1016/j.arbres.2014.01.011

7. Hernández-Pérez JM, Ramos-Díaz R, Vaquerizo-Pollino C, Pérez JA. Frequency of alleles and genotypes associated with Alpha-1 antitrypsin deficiency in clinical and general populations: revelations about underdiagnosis. *Pulmonology*. 2022. doi:10.1016/j.pulmoe.2022.01.017